Companies /Healthcare

Ocugen Inc

NASDAQ: OCGN Biotechnology
$1.05
▲ $0.03 (+2.44%) today
Markets open · 11:49am ET

Q2 2025 Earnings

Reported Aug 1, 2025, 12:23pm ET · SEC source
$-0.05
Beat +11.82%
EPS · est. $-0.06
$1.4M
Beat +292.29%
Revenue · est. $350,000
+2.1%
Beating market
OCGN vs S&P since report
4 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−3%0+3%Aug 1Aug 1report 12:23pm ETearnings−0.5%−0.3%
−3%0+3%Aug 1Aug 1earnings−0.5%−0.3%
OCGN −0.3%S&P 500 −0.5%
−3%0+3%Aug 1Aug 1report 12:23pm ETearnings−0.7%−0.3%
−3%0+3%Aug 1Aug 1earnings−0.7%−0.3%
OCGN −0.3%NASDAQ −0.7%
−4%0+4%Jul 31Aug 8report 12:23pm ETearnings+2.8%+0.7%
−4%0+4%Jul 31Aug 8earnings+2.8%+0.7%
OCGN +0.7%S&P 500 +2.8%
−4%0+4%Jul 31Aug 8report 12:23pm ETearnings+4.0%+0.7%
−4%0+4%Jul 31Aug 8earnings+4.0%+0.7%
OCGN +0.7%NASDAQ +4.0%
−3.50%
Day of report
+0.60%
Next session
+0.40%
One week
+5.63%
30 days

S&P 500 over the same 30 days: +3.54%.

Did OCGN Beat Earnings? Q2 2025 Results

Ocugen delivered a stronger-than-expected second quarter, beating Wall Street estimates on both the top and bottom lines as its modifier gene therapy pipeline continued to advance toward multiple regulatory milestones. The clinical-stage ophthalmology company posted a loss of $0.05 per share, ahead of the consensus estimate of $0.06 by 11.82%, while revenue of $1.37 million cleared the $350,000 analyst target by 292.29% and grew 20.3% year-over-year, driven by collaborative arrangement income that included a binding term sheet for exclusive Korean rights to OCU400 carrying upfront and milestone payments of up to $11.00 million. Operating discipline also helped, with total expenses falling to $15.17 million from $16.59 million a year earlier. The quarter's strategic headline was a proposed reverse merger of subsidiary OrthoCellix with Carisma Therapeutics, valuing OrthoCellix at roughly $135.00 million and designed to surface NeoCart's value while keeping capital focused on the gene therapy platform. Looking ahead, the company is targeting BLA filings for OCU400 in 2026, OCU410ST in 2027, and OCU410 in 2028, though cash of $27.32 million provides runway only into Q1 2026.

Key Takeaways
  • Collaborative arrangement revenue of $1.4 million in Q2 2025
  • Lower R&D expenses ($8.4M vs $8.9M) and G&A expenses ($6.8M vs $7.7M) year-over-year
  • Narrower net loss per share of -$0.05 vs -$0.06 in Q2 2024

“While our modifier gene therapy clinical trials advance—now with two in late-stage—we are securing strategic partnerships and evolving the business to support three successful Biologics License Application (BLA) filings over the next three years.”

Ocugen CEO, on the earnings call

Forward Guidance & Outlook

Ocugen targets three BLA filings over the next three years: OCU400 BLA/MAA submissions in 2026 for retinitis pigmentosa, OCU410ST BLA submission by 2027 for Stargardt disease, and OCU410 BLA submission by 2028 for geographic atrophy. The company expects to complete OCU400 manufacturing process validation this year and complete the OCU200 Phase 1 trial in the second half of 2025. NIAID intends to initiate the Phase 1 clinical trial for OCU500 in Q3 2025. The company's cash runway extends into Q1 2026. The OrthoCellix reverse merger with Carisma Therapeutics is intended to unlock value from NeoCart while enabling focus of capital on the modifier gene therapy platform. The company is pursuing additional regional partnership opportunities for OCU400 and all gene therapy candidates.

OCGN YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-15,000,000$-10,000,000$-5,000,000$0$1.1M$1.4MRevenue$-12,460,482$-13,795,000Operating Income$-14,235,078$-14,739,000Net Income
$-15,000,000$-10,000,000$-5,000,000$0RevenueOperating IncomeNet Income

OCGN Revenue by Segment

Collaborative Arrangement Revenue

Figures from SEC filings and company reports. Not investment advice.